[Characteristics of recurrence of T1G3 transitional cell carcinoma of bladder].

Zhonghua Yi Xue Za Zhi

Department of Urology, Peking Union Medical College Hospital, Peking Medical College, Beijing 1200730, China.

Published: May 2006

Objective: To investigate the characteristics of recurrence of T1G3 transitional cell carcinoma (TCC) of bladder.

Methods: The clinical data of 72 patients with TCC of bladder of the stage T1, 37 being of the stage T1G3 and 35 being of the stage T1G1-2, who underwent the initial treatment by transurethral resection of bladder tumor plus post-operative bladder infusion were analyzed.

Results: The first, second, third, and fourth year recurrent rates of the T1G3 group were 29.7%, 40.5%, 18.9%, and 10.8% respectively, all significantly higher than those of the T1G2 group (14.3%, 34.3%, 31.4%, and 20.0% respectively, t = 1.994, P = 0.025). The rate of recurrence for only time was 10.8% in the T1G3 group (4/37), significantly lower than that of the T1G1-2 group (17/35, 48.6%, P < 0.01). The rate of recurrence for more than 3 times was 54.0% in the T1G3 group (20/37), significantly higher than that of the T1G1-2 group (6/35, 17.2%, P < 0.01). The rate of recurrent tumor at the pathological stage over T2 was 86.5% (32/37) in the T1G3 group, higher than that of the T1G1-2 group (42.8%, 15/35). The rate of partial or total cystectomy at the last recurrence in the T1G3 group was 94.6% (35/37), significantly higher than that of the T1G1-2 group (57.1%, 20/35, chi(2) = 14.00, P < 0.05).

Conclusion: A kind of dangerous bladder cancer, TCC at the stage T1G3 is apt recur soon after the treatment with a high recurrent frequency. Most recurrent tumors evolve into invasive cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

t1g3 group
20
t1g1-2 group
16
recurrence t1g3
12
higher t1g1-2
12
group
10
t1g3
9
t1g3 transitional
8
transitional cell
8
cell carcinoma
8
stage t1g3
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!